General Information of Drug (ID: DMIM5DL)

Drug Name
6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one Drug Info
Synonyms CHEMBL462093; 6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one; 2(1H)-Naphthalenone,3,4-dihydro-6-(3-pyridinyl)-; BDBM50273703
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
25180108
TTD Drug ID
DMIM5DL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
PMX-53 DMZUAJ4 Atopic dermatitis EA80 Phase 2 [3]
BMS-536924 DMXJB4N Discovery agent N.A. Investigative [4]
Heme DMGC287 Discovery agent N.A. Investigative [5]
ML-3163 DM3S5UC Discovery agent N.A. Investigative [6]
6-(3-Hydroxy-phenyl)-naphthalen-2-ol DMH8WA2 Discovery agent N.A. Investigative [7]
2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole DMZVBPG Discovery agent N.A. Investigative [8]
ML-3375 DMXJY6W Discovery agent N.A. Investigative [6]
ML-3403 DMTQWI8 Discovery agent N.A. Investigative [6]
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol DM7ERYJ Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [10]
Osilodrostat DMIJC9X Cushing disease 5A70 Approved [11]
Metyrapone DMI7FVQ Cushing disease 5A70 Approved [12]
4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol DM6Z5EK Discovery agent N.A. Investigative [13]
4-Indan-(1Z)-ylidenemethyl-pyridine DM25DR7 Discovery agent N.A. Investigative [14]
4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine DMIEMWA Discovery agent N.A. Investigative [13]
4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine DMY08FE Discovery agent N.A. Investigative [14]
5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine DM2RIHT Discovery agent N.A. Investigative [14]
4-((1H-imidazol-1-yl)methyl)benzonitrile DMFUBRC Discovery agent N.A. Investigative [10]
4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine DMHDZUO Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Albendazole monooxygenase (CYP3A4) TTXV4FI CP3A4_HUMAN Inhibitor [1]
Steroid 11-beta-hydroxylase (CYP11B1) TTIQUX7 C11B1_HUMAN Inhibitor [1]

References

1 In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87.
2 Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31.
3 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
4 Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)py... J Med Chem. 2008 Oct 9;51(19):5897-900.
5 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
6 Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
7 Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
8 Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
9 New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
10 Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
12 Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In Vitro. 2002 Apr;16(2):113-21.
13 Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
14 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.